Abstract

Review Article

Primary prevention of SCD with ICD in the elderly

Fabio Maria Gemelli*, Lucia Mancinelli, Olga Protic, Lorenzo Pimpini and Roberto Antonicelli

Published: 30 March, 2020 | Volume 5 - Issue 1 | Pages: 067-072

Implantable cardioverter defibrillators (ICDs) are electronic devices that can prevent sudden cardiac death (SCD) caused by arrhythmic events in patients.

The latest ESC/EAS and ACC/AHA Guidelines deem the placement of an ICDs appropriate in patients with heart failure class NYHA II and III in the presence of an ejection fraction less than or equal to 35% [1,2]. ICDs are usually not indicated in either class I or IV patients. The Guidelines recommendations for primary prevention of SCD with ICD implantation do not take into account the age of the patients but only their life expectancy which must be at least 1 year.

Our patients usually are over eighty years old with heart failure and severely reduced ejection fraction. We must consequently decide if it is right to implant these patients with an ICD. Is the use of ICD in the patients over 80, in particular over 90 years old, really make sense becomes particularly important considering demographic changes that await us in the coming decades.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001089 Cite this Article Read Full Article PDF

References

  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37: 2129-2200. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27206819
  2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128: e240-e327. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23747642
  3. Kirk D. Demographic transition theory. Popul Stud (Camb). 1996; 50: 361-387. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11618374
  4. VII Rapporto RBM - Censis sulla Sanità Pubblica, Privata e Intermediata. Luglio 2017.
  5. Bibas L, Levi M, Touchette J, Mardigyan V, Bernier M, et al. Implications of Frailty in Elderly Patients With Electrophysiological Conditions. JACC Clin Electrophysiol. 2016; 2: 288-294. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29766886
  6. Chen MY, Orkaby AR, Rosenberg MA, Driver JA. Frailty, Implantable Cardioverter Defibrillators, and Mortality: A Systematic Review. J Gen Intern Med. 2019; 34: 2224-2231. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31264082
  7. Sherman H, Sandberg S, Fineberg HV. Exponential increase in age-specific prevalence of ventricular dysrhythmia among males. J Chronic Dis. 1982; 35: 743-750. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6179958
  8. Raybaud F, Camous JP, Tibi T, Baudouy M, Morand P. Severe arrhythmias in the elderly: a prospective hospital study. Arch Mal Coeur Vaiss. 1995; 88: 27-33. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7646246
  9. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. J Clin Invest. 2005; 115: 2305-2315. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16138184
  10. Yung D, Birnie D, Dorian P, Healey JS, Simpson CS, et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation. 2013; 127: 2383-2392. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23775193
  11. Chugh SS1, Jui J, Gunson K, Stecker EC, John BT, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large US community. J Am Coll Cardiol. 2004; 44: 1268-1275. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15364331
  12. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-883. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11907286
  13. Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML,, et al. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II sub study. J Cardiovasc Electrophysiol. 2007; 18: 833-838. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17537209
  14. Kong MH, Al-Kathib SM, Sanders GD, Hasselbland V, Peterson ED. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. Cardiol J. 2011; 18: 503-514. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21947985
  15. Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, et al. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes. 2009; 2: 16-24. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20031808
  16. Yung D, Birnie D, Dorian P, Healey JS, Simpson CS, et al. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation. 2013; 127: 2383-2392. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23775193
  17. Adelstein EC, Liu J, Jain S, Schwartzman D, Althouse AD, et al. Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older. Europace. 2016; 18: 420-427. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26487669
  18. Al-Khatib SM, Greiner MA, Peterson ED, Hernandez AF, Schulman KA, et al. Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythmia Electrophysiol. 2008; 1: 240-149. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19169382
  19. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225-2237. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15659722
  20. Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter defibrillators. Ann Intern Med. 2010; 153: 592-599. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21041579
  21. Fauchier L, Marijon E, Defaye P, Piot O, Sadoul N, et al. Effect of age on survival and causes of death after primary prevention implantable cardioverter defibrillator implantation. Am J Cardiol. 2015; 115: 1415-1422. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25784518
  22. Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, et al. Role of implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007; 28: 1746-1749. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17283003
  23. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients with Nonischemic Systolic Heart Failure. Circulation.2017; 136: 1772–1780. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28877914
  24. Manian U, Gula LJ. Arrhythmia Management in the Elderly-Implanted Cardioverter Defibrillators and Prevention of Sudden Death. Can J Cardiol. 2016; 32: 1117-1123. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27568872
  25. Clegg A, Young J, Iliffe S, Rikkert MO and Rockwood K. Frailty in elderly people. Lancet. 2013; 381: 752-62. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23395245
  26. Andela RM, Dijkstra A, Slaets JP, Sanderman R. Prevalence of frailty on clinical wards: description and implications. Int J Nurs Pract. 2010; 16: 14–19. Epub 2010/02/18. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20158543
  27. Kubala M, Guédon-Moreau L, Anselme F, Klug D, Bertaina G, et al. Utility of Frailty Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy. JACC Clin Electrophysiol. 2017; 3: 1523-1533. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29759834
  28. Setoguchi S, Warner Stevenson L, Stewart GC, Bhatt DL, Epstein AE, et al. Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. BMJ. 2014; 8: 348: g2866. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24812112
  29. Warmoth K, Lang IA, Phoenix C, et al. “Thinking you’re old and frail”: a qualitative study of frailty in older adults. Ageing Soc. 2016; 36: 1483-500.
  30. Dresden SM, Platts-Mills TF, Kandasamy D, Walden L, Betz ME. Patient versus Physician Perceptions of Frailty: A comparison of Clinical Frailty Scale Scores of Older Adults in the Emergency Departement. Acad Emerg Med. 2019; 26: 1089-1092. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31265194
  31. Datino T, Miracle Blanco Á, Núñez García A, González-Torrecilla E, Atienza Fernández F, et al. Safety outpatient implantation of the implantable cardioverter-defibrillator. Rev Esp Cardiol. 2015; 68: 579-584. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25435093
  32. McMurray JJ1, Adamopoulos S, Anker SD, Auricchio A, Böhm M,, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the ESC. Developed in collaboration with HFA of the ESC. Eur Heart J. 2012; 33: 1787-1847. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22611136
  33. Azad N, Kathiravelu A, Minoosepeher S, Herbert P, Fergusson D. Gender difference in the aetiology of heart failure: a systematic review. J Geriatr Cardiol. 2011; 8: 15-23. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22783280
  34. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, et al. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009; 32: 1119-1131. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19429873
  35. Wittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, et al. Comparison of efficacy of implanted cardioverter defibrillator in patients with versus without diabetes mellitus. Am J Cardiol. 2005; 96: 417-419. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16054472
  36. Fantoni C, Regoli F, Ghanem A, Raffa S, Klersy C, et al. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail. 2008; 10: 298-307. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18296111
  37. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003; 91: 2D-8D. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12670636
  38. van Boven N, Theuns D, Bogaard K, Ruiter J, Kimman G, et al. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks. J Cardiovasc Electrophysiol. 2013; 24: 1116-1122. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23889733
  39. Deo R, Sotoodehnia N, Katz R, Sarnak MJ, Fried LF, et al. Cystatin C and sudden cardiac death risk in the elderly. Circ Cardiovasc Qual Outcomes. 2010; 3: 159–164. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20233980
  40. Bansal N, Szpiro A, Masoudi F, Greenlee RT, Smith DH, et al. Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators. Heart. 2017; 103: 529-537. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27742796
  41. Kubala M, Guédon-Moreau L, Anselme F, Klug D, Bertaina G, et al. Utility of Frailty Assessment for Elederly Patients Undergoing Cardiac Resynchronization Therapy. JACC Clin Electrophysiol. 2017; 30: 1523-1533. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29759834
  42. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischaemic left ventricular dysfunction. J Am Coll Cardiol. 2008; 51: 288-296. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18206738
  43. Anné W, Schaer B, Van Belle Y, Szili-Torok T, Smith T, et al. ICDs at higher age and clinical risk factors. Neth Heart J. 2014; 22: 279-285. https://www.ncbi.nlm.nih.gov/pubmed/24795210
  44. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2012; 60: 1647-1655. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23021331
  45. Kraier K, Scholten MF, Tijssen JG, Theuns DA, Jordaens LJ, et al. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score. Europace. 2014; 16: 40-46. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23918791
  46. Chong D, Tan BY, Ho KL, Liew R, Teo WS, et al. Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation. Europace. 2013; 15: 508-514. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22848076

Figures:

Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?